医学
肺癌
肿瘤微环境
抗药性
疾病
癌症
免疫系统
免疫检查点
免疫学
人口
免疫疗法
肿瘤科
癌症研究
内科学
生物
环境卫生
微生物学
作者
Kexun Zhou,Shuo Li,Yi Zhao,Ke Cheng
标识
DOI:10.3389/fimmu.2023.1127071
摘要
Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI